Résumé
Les SMD représentent l’hémopathie la plus fréquente du sujet âgé. Un syndrome anémique est le mode de révélation habituel, le diagnostic est confirmé par le médullogramme. Le pronostic repose sur le nombre de cytopénies, le pourcentage de blastes médullaires et le caryotype. Compte-tenu du terrain, l’évaluation des comorbidités va conditionner les modalités de prise en charge. Les SMD sont séparés en deux groupes: les SMD de faible risque dont le traitement consiste à prendre en charge l’anémie (traitement par érythropoïétine, transfusions sanguines) et les SMD de haut risque pour lesquels l’enjeu est de contrôler l’évolution vers la leucémie aiguë. Ce dernier groupe de patients bénéficie d’une avancée thérapeutique majeure en 2008 avec l’obtention de l’AMM pour le premier médicament en Europe dans cette indication.
This is a preview of subscription content, log in via an institution to check access.
Preview
Unable to display preview. Download preview PDF.
Références
Aul C, Gattermann N, Schneider W. Epidemiological and etiological aspects of myelodysplastic syndromes. Leuk Lymphoma. 1995; 16:247–262.
Fain O, Hamidou M, Cacoub P, et al. Vasculitides associated with malignancies: analysis of sixty patients. Arthritis Rheum. 2007; 57:1473–1480.
Bennett JM, Komrokji RS. The myelodysplastic syndromes: diagnosis, molecular biology and risk assessment. Hematology. 2005; 10:258–269.
Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997 World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. Ann Oncol 1999; 10:1419–1432.
Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89:2079–2088.
Fontenay M, Gyan E. Apoptotic pathways to death in myelodysplastic syndromes. Haematologica. 2008; 93:1288–1292.
Beyne-Rauzy O, Prade-Houdellier N, Demur C, et al. Tumor necrosis factor-alpha inhibits hTERT gene expression in human myeloid normal and leukemic cells. Blood. 2005; 106:3200–3205. Epub 2005 Jul 14.
Sorror ML, Sandmaier BM, Storer BE, et al. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol. 2007; 25:4246–4254. Epub 2007 Aug 27.
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009; 10:223–232. Epub 2009 Feb 21.
Park S, Grabar S, Kelaidi C, et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood. 2008; 111:574–582. Epub 2007 Oct 16.
List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006; 355:1456–1465.
Author information
Authors and Affiliations
Editor information
Rights and permissions
Copyright information
© 2011 Springer-Verlag France
About this chapter
Cite this chapter
Beyne-Rauzy, O. (2011). Les syndromes myélodysplasiques. In: Balardy, L., Gérard, S., Mourey, L., Vellas, B., Rainfray, M. (eds) Oncogériatrie. Springer, Paris. https://doi.org/10.1007/978-2-8178-0142-1_18
Download citation
DOI: https://doi.org/10.1007/978-2-8178-0142-1_18
Publisher Name: Springer, Paris
Print ISBN: 978-2-8178-0141-4
Online ISBN: 978-2-8178-0142-1
eBook Packages: MedicineMedicine (R0)